Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 5.60
Day High 5.87
Open:5.83
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not currently operate in the U.S. due to federal prohibition. The company is focusing on expanding through international cultivation and distribution into the global medical cannabis market. Aphria also offers multiple products under a portfolio of recreational cannabis brands, including Solei, RIFF, and Broken Coast.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports+

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Aphria Announces Issuance of Shares in Respect of Previously Announced Settlement of Claim
- PR Newswire - PRF - Mon Jul 6, 8:25AM CDT
PR Newswire - PRF - CMTX
Mon Jul 6, 8:25AM CDT
LEAMINGTON, ON, /PRNewswire/ - Aphria Inc. ("") (TSX: APHA and NASDAQ: APHA), a leading global cannabis company, today announced that it has issued 1,658,375 common shares (the "") to Emblem Cannabis Corporation (""), a wholly owned subsidiary of Aleafia Health Inc. (TSX: AH, OTC: ALEAF) ("") as part of a settlement agreement entered into between the parties and previously disclosed on .
Aphria Announces Issuance of Shares in Respect of Previously Announced Settlement of Claim
- PR Newswire - Mon Jul 6, 8:25AM CDT
PR Newswire - PRNW
Mon Jul 6, 8:25AM CDT
LEAMINGTON, ON, July 6, 2020 /PRNewswire/ - Aphria Inc. (" Aphria ") (TSX: APHA and NASDAQ: APHA), a leading global cannabis company, today announced that it has issued 1,658,375 common shares (the " Settlement Shares ") to Emblem Cannabis Corporation (" Emblem "), a wholly owned subsidiary of Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (" Aleafia Health ") as part of a settlement agreement entered into between the parties and previously disclosed on June 25, 2020 .
Regulators Move to Remove Restriction on Some Uses of Psilocybin
- PR Newswire - PRF - Mon Jul 6, 8:00AM CDT
PR Newswire - PRF - CMTX
Mon Jul 6, 8:00AM CDT
, /PRNewswire/ -- The political push for the legalization of psychedelic products is now underway. Earlier this week, an ballot measure to legalize the use of psilocybin, a naturally occurring psychedelic prodrug compound, in a therapeutic setting has attracted enough signatures to be featured on the November ballot, under the condition that these signatures can be verified. "Pioneering research at institutions like , , and has shown the significant promise of psilocybin therapy," said a press release put out by the campaign Monday, according to . "especially for people whose depression or anxiety hasn't responded to other available treatments." If successful, will become the first state to legalize a psychedelic substance, which is currently classified as a Schedule I drug. Previously, only cities like and have decriminalized the use of psilocybin. Earlier in , has passed a ballot measure decriminalizing psilocybin. Just less than a month after, the city council of passed a similar resolution. Mydecine Innovations Group Inc. (OTC: MYCOF) (CSE: MYCO), Novartis AG (NYSE: NVS), Pfizer Inc. (NYSE: PFE), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Aphria Inc. (NYSE: APHA) (TSX: APHA).
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 5.43 +4.60% increase
on 06/29/20
Period Open:6.78
Price movement based on the high, low and last over the given period.
6.97 -18.51% decrease
on 06/10/20
-1.10 (-16.22%) decrease
since 06/09/20
3-Month 3.93 +44.53% increase
on 05/14/20
Period Open:4.42
Price movement based on the high, low and last over the given period.
7.04 -19.32% decrease
on 06/09/20
+1.26 (+28.51%) increase
since 04/09/20
52-Week 2.65 +114.34% increase
on 03/16/20
Period Open:8.87
Price movement based on the high, low and last over the given period.
10.05 -43.48% decrease
on 08/06/19
-3.19 (-35.96%) decrease
since 07/09/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies